Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women

World Journal of Surgical Oncology

Dar-Ren Chen⁴  Tsai-Wang Chang¹  Shou-Tung Chen⁵  Shou-Jen Kuo⁴  Su-Yu Chien³  Szu-Erh Chan²  Che Lin⁴  Hsin-Shun Tseng⁵ 

[1] Department of Surgery, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan;Department of Surgical Medicine, Erlin Branch of Changhua Christian Hospital, Changhua 52665, Taiwan;Department of Pharmacology, Changhua Christian Hospital, Changhua 50006, Taiwan;School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan;Comprehensive Breast Cancer Center, Changhua Christian Hospital, 135 Nanhsiao Street, Changhua 50006, Taiwan

关键词: Hormone receptor;    Prognosis;    Infiltrating ductal carcinoma;    Mucinous carcinoma;   

Others  :  823819
DOI  :  10.1186/1477-7819-11-139

 received in 2013-01-25, accepted in 2013-05-12,  发布年份 2013

【 摘 要 】

Background

Pure mucinous carcinoma (MC) is found in about 3.5% of all newly diagnosed breast cancer patients in Taiwan. MC is a relatively rare malignancy of breast cancer, and its nature, behaviors, treatment pattern and long-term follow-up are not well understood. The study aimed to investigate the incidence rate, treatment patterns, and prognostic factors of MC of the breast and the clinical long-term outcomes compared with infiltrating ductal carcinoma not otherwise specified (IDC) in the middle and south Taiwanese women.

Methods

Data from 93 patients with breast MC were retrospectively reviewed and the clinicopathologic characteristics and survival status were compared with those of 2,674 patients with IDC.

Results

The expression of hormonal receptor was higher in MC than those in IDC (P <0.001). MC also demonstrated lower Her2/neu gene over-expression (P = 0.023), less axillary lymph node involvement (P <0.0001), lymphovascular invasion (P <0.0001) and higher 10-year overall survival rate (P = 0.042), when compared with those of IDC.

Conclusion

Our data confirm the less aggressive behavior of MC compared to IDC. MC showed favorable clinicopathologic characteristics in tumor grade, hormone receptor status and lymph node involvement in the middle and south Taiwanese women.

【 授权许可】

   
2013 Tseng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Komaki K, Sakamoto G, Sugano H, Morimoto T, Monden Y: Mucinous carcinoma of the breast in Japan. A prognostic analysis based on morphologic features. Cancer 1988, 61:989-996.
• [2]Louwman MW, Vriezen M, van Beek MW, Nolthenius-Puylaert MC, van der Sangen MJ, Roumen RM, Kiemeney LA, Coebergh JW: Uncommon breast tumors in perspective: incidence, treatment and survival in the Netherlands. Int J Cancer 2007, 121:127-135.
• [3]National Comprehensive Cancer Network: Breast cancer. In NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) (National Comprehensive Cancer Network ed., vol. 2012, v1.2012 edition. Fort Washington, PA: National Comprehensive Cancer Network; 2012. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf webcite
• [4]Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM: Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999, 17:1442-1448.
• [5]Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW: Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992, 20:479-489.
• [6]Tyagi R, Kumar M, Tanwar P, Dey P: Mucinous carcinoma of breast: FNAC as effective diagnostic modality. Asian J Med Sci 2012, 3:32-35.
• [7]Tan JZ, Waugh J, Kumar B, Evans J: Mucinous carcinomas of the breast: imaging features and potential for misdiagnosis. J Med Imaging Radiat Oncol 2013, 57:25-31.
• [8]Ranade A, Batra R, Sandhu G, Chitale RA, Balderacchi J: Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. J Clin Pathol 2010, 63:1043-1047.
• [9]Cho LC, Hsu YH: Expression of androgen, estrogen and progesterone receptors in mucinous carcinoma of the breast. Kaohsiung J Med Sci 2008, 24:227-232.
• [10]Di Saverio S, Gutierrez J, Avisar E: A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008, 111:541-547.
• [11]Komenaka IK, El-Tamer MB, Troxel A, Hamele-Bena D, Joseph KA, Horowitz E, Ditkoff BA, Schnabel FR: Pure mucinous carcinoma of the breast. Am J Surg 2004, 187:528-532.
• [12]Lesser ML, Rosen PP, Senie RT, Duthie K, Menendez-Botet C, Schwartz MK: Estrogen and progesterone receptors in breast carcinoma: correlations with epidemiology and pathology. Cancer 1981, 48:299-309.
• [13]Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
• [14]Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004, 364:858-868.
• [15]Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
• [16]Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A, Reis-Filho JS: Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010, 222:282-298.
• [17]Bae SY, Choi MY, Cho DH, Lee JE, Nam SJ, Yang JH: Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer 2011, 14:308-313.
• [18]Toikkanen S, Eerola E, Ekfors TO: Pure and mixed mucinous breast carcinomas: DNA stemline and prognosis. J Clin Pathol 1988, 41:300-303.
• [19]Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM: Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat 2013, 137:431-448.